Results 21 to 30 of about 162,494 (358)
Impact of Direct Oral Anticoagulant Uptake on Hospitalizations for Stroke/Transient Ischemic Attack, Intracranial Hemorrhage, and Gastrointestinal Bleeding in Individuals With Atrial Fibrillation: A Population-Based Study. [PDF]
Fundam Clin PharmacolABSTRACT Background Direct‐acting oral anticoagulants (DOACs) have largely replaced warfarin for stroke prevention in patients with atrial fibrillation, yet their population‐level impact on health outcomes and costs remains unclear. We examined whether the widespread uptake of DOACs was associated with changes in hospitalization rates and costs for ...
Antoniou T +4 more
europepmc +2 more sources
Adjustment for 'Prescriber Type' in Pharmacoepidemiological Analyses. [PDF]
Basic Clin Pharmacol ToxicolABSTRACT The type of prescriber typically fulfils the criteria for confounding, as it is associated both with the exposure (e.g., prescriber types may differ in their choice of first‐line treatment) and with the outcome (as different types of prescribers often treat patients with different disease severity).
Abbasi SH +4 more
europepmc +2 more sources
INTERACTIONS OF WARFARIN [PDF]
Biomedical Papers, 2001 In this article, the author reviews and updates the basis of interactions with warfarin, illustrated with appropriate examples. The interactions with drugs, medicinal herbs and foods are summarised.
openaire +3 more sources
Evaluation of pharmacokinetics of warfarin from validated pharmacokinetic-pharmacodynamic model
ADMET and DMPK, 2021 Background: Pharmacokinetics of warfarin has not been described in our population. We derived the pharmacokinetic parameters from a validated pharmacokinetic-pharmacodynamic model. Methods: Patients receiving warfarin for at least 6 months were recruited
Kannan Sridharan +2 more
doaj +1 more source
Risk factors of ischemic stroke and subsequent outcome in hemodialysis patients [PDF]
, 2015 Background and purpose: End stage renal disease (ESRD) requiring hemodialysis (HD) carries up to a 10-fold greater risk of stroke than normal renal function. Knowledge concerning risk factors and management strategies derived from the general population
Dawson, Jesse +9 more
core +1 more source
Warfarin pharmacogenetics [PDF]
Trends in Cardiovascular Medicine, 2015 The cytochrome P450 (CYP) 2C9 and vitamin K epoxide reductase complex 1 (VKORC1) genotypes have been strongly and consistently associated with warfarin dose requirements, and dosing algorithms incorporating genetic and clinical information have been shown to be predictive of stable warfarin dose.
Julie A, Johnson, Larisa H, Cavallari
openaire +2 more sources
Thrombosis Journal, 2008 Introduction Atrial fibrillation affects an estimated 2.5 million Americans and incurs an average annual stroke risk of 4.5% per year. Despite warfarin reducing stroke risk by approximately 66%, prior studies show warfarin usage rates to be about 50 ...
Cavalcante Joao +5 more
doaj +1 more source
Scientific Reports, 2017 Recent global deregulation of ginseng as the table food raises our concern about the possible ginseng-warfarin interaction that could be life-threatening to patients who take warfarin for preventing fatal strokes and thromboembolism while using ginseng ...
Haiyan Dong +8 more
doaj +1 more source
Pharmaceutics, 2022 Warfarin is extensively used for venous thromboembolism and other coagulopathies. In clinical settings, warfarin is administered as a mixture of S- and R-warfarin, and both enantiomers are metabolized by multiple cytochrome P450 enzymes into many ...
Shasha Jin +6 more
doaj +1 more source
Update on Extended Treatment for Venous Thromboembolism [PDF]
, 2018 The importance of assessing the probability of venous thromboembolism recurrence, a condition that includes deep vein thrombosis and pulmonary embolism, lies in the fact that it is the most important factor in deciding the duration of anticoagulant ...
Del Toro-Cervera, Jorge +7 more
core +2 more sources